- Home
- EWCZ vs PROK Comparison
EWCZ vs PROK Comparison
Compare EWCZ & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWCZ | PROK |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.7M | 296.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EWCZ | PROK |
|---|---|---|
| Price | $5.82 | $1.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $5.87 | ★ $7.40 |
| AVG Volume (30 Days) | 390.6K | ★ 1.0M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $3.76 | N/A |
| Revenue Next Year | $2.29 | N/A |
| P/E Ratio | $21.96 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $2.95 | $0.54 |
| 52 Week High | $6.52 | $7.13 |
Technical Indicators
Market Signals| Indicator | EWCZ | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 42.25 |
| Support Level | $3.53 | $1.71 |
| Resistance Level | $5.90 | $2.58 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 30.00 | 1.39 |
Price Performance
Historical ComparisonAbout EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services, and others.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.